Literature DB >> 3190194

In vitro activity of U-76,252 (CS-807), a new oral cephalosporin.

R J Fass1, V L Helsel.   

Abstract

U-76,252 is the prodrug of U-76,253. MICs of U-76,253 were 0.015 to 0.06 microgram/ml for greater than or equal to 90% of the strains of Streptococcus spp., Haemophilus influenzae, and Proteus mirabilis; 0.25 to 1 microgram/ml for Branhamella catarrhalis, Escherichia coli, Klebsiella spp., and Citrobacter diversus; 1 to 8 micrograms/ml for Staphylococcus spp.; and 2 to greater than 16 micrograms/ml for other members of the family Enterobacteriaceae and Aeromonas hydrophila; for 72% of the latter group, MICs were less than or equal to 4 micrograms/ml. MICs for Pseudomonas aeruginosa and Enterococcus faecalis were greater than 16 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190194      PMCID: PMC172349          DOI: 10.1128/AAC.32.7.1082

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  Susceptibility of Enterobacter to cefamandole: evidence for a high mutation rate to resistance.

Authors:  C M Findell; J C Sherris
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

2.  In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.

Authors:  Y Utsui; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  Modified microdilution susceptibility test for staphylococci, streptococci and Haemophilus spp.

Authors:  R J Fass; V L Helsel
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

  3 in total
  17 in total

1.  In vitro activity of cefpodoxime against staphylococci in comparison to other cephalosporins.

Authors:  F Schumacher-Perdreau; B Jansen; G Peters
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

2.  Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.

Authors:  J V St Peter; M T Borin; G S Hughes; J S Kelloway; B E Shapiro; C E Halstenson
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 3.  A review of the pharmacokinetics of cefpodoxime proxetil.

Authors:  M T Borin
Journal:  Drugs       Date:  1991       Impact factor: 9.546

4.  Microbiological evaluation of cefpodoxime proxetil.

Authors:  B Wiedemann; E Luhmer; M T Zühlsdorf
Journal:  Drugs       Date:  1991       Impact factor: 9.546

5.  Penetration of cefpodoxime into uterine and vaginal secretions from postpartum women after a single oral dose of cefpodoxime proxetil.

Authors:  N Takasugi; N Tsunaga; N Sugino; F Numa; H Kato
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

6.  Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.

Authors:  N Saathoff; H Lode; K Neider; K M Depperman; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

7.  Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.

Authors:  C C Knapp; J Sierra-Madero; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

8.  Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis.

Authors:  D Höffler; P Koeppe; M Corcilius; A Przyklinik
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

9.  Comparative in vitro activity of cefpodoxime against anaerobes other than Bacteroides fragilis.

Authors:  H Werner; W R Heizmann; M Höflsauer
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

10.  Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.

Authors:  H Knothe; P M Shah; O Eckardt
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.